Rabies is a deadly viral infection that, once symptoms appear, almost always leads to death—but it is one of the few fatal diseases that can be completely prevented if treatment begins quickly after exposure.

How We Fight a Virus That Allows No Second Chances

The approach to rabies is unlike most other diseases. Instead of waiting for symptoms to guide treatment decisions, the entire medical response is built around prevention. This is because rabies has a nearly 100% fatality rate once symptoms begin, but it is also almost 100% preventable with prompt care after exposure.^[1] The goal is always to stop the virus before it reaches the brain and spinal cord, where it causes irreversible damage.

Treatment strategies depend heavily on whether a person seeks help before or after symptoms develop. For those exposed to the virus—through a bite, scratch, or contact with infected saliva—immediate medical intervention can save lives. For individuals at high risk of exposure, such as veterinarians or travelers to areas where rabies is common in dogs, preventive vaccination before any contact with the virus offers an additional layer of protection.^[12]

Around the world, approximately 59,000 people die from rabies each year, with the vast majority of cases occurring in Asia and Africa where dog bites are the primary source of infection.^[2] In the United States, fewer than three people die from rabies annually, thanks to widespread vaccination of pets, public health programs, and the availability of medical treatment after exposure.^[1] Despite this low number, around 100,000 Americans receive preventive treatment each year after potential rabies exposure, demonstrating the serious public health threat this virus continues to pose.^[1]

Medical guidelines from organizations like the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) provide detailed protocols for managing rabies exposure. These recommendations cover everything from wound care immediately after a bite to the precise schedule for vaccine administration. Healthcare providers must act quickly, as delays can mean the difference between life and death. Once the virus enters the nervous system and symptoms emerge, medical care can only provide comfort—there is no cure.^[2]

Standard Treatment After Exposure to Rabies

The cornerstone of rabies prevention after exposure is called post-exposure prophylaxis, or PEP. This treatment protocol has three essential components, all of which must be completed to ensure protection. The first and most immediate step is thorough wound cleaning. Anyone who has been bitten or scratched by an animal that might carry rabies should immediately wash the wound with soap and water for at least 15 minutes.^[17] This physical flushing action can remove much of the virus before it has a chance to enter nerve cells. Following the water rinse, applying an antiseptic solution can further reduce viral load at the wound site.^[10]

The second component is human rabies immune globulin, often abbreviated as HRIG. This biological medicine contains antibodies taken from the blood of human donors who have high levels of rabies-fighting proteins.^[13] HRIG provides immediate, passive protection by delivering ready-made antibodies directly to the site where the virus entered the body. A healthcare provider injects as much of the HRIG as possible directly into and around the wound. If the wound is too small or located in a difficult area, the remaining dose is injected into a muscle, often in the upper arm or thigh.^[13] HRIG is critical because vaccines take time to work, and this medicine fills the gap, neutralizing any virus particles before they can spread.

However, HRIG is not given to everyone. People who have previously received the complete rabies vaccine series—either before exposure or during a previous treatment—already have some immune memory and do not need HRIG. For them, antibodies from the vaccine will respond more quickly.^[10] HRIG should be administered as soon as possible, ideally at the same time as the first vaccine dose, but it can be given up to seven days after the first vaccination. After seven days, the vaccine is assumed to have started generating an immune response, making HRIG unnecessary.^[13]

The third and most crucial component is the rabies vaccine series. For individuals who have never been vaccinated against rabies, the standard protocol involves four doses of vaccine given over 14 days. The first dose is administered as soon as possible after exposure—this is considered “day 0.” Additional doses follow on days 3, 7, and 14.^[10] For people who have previously been vaccinated, only two doses are needed, given on days 0 and 3.^[10] The vaccine is injected into the deltoid muscle of the arm for adults and older children, while young children may receive it in the thigh muscle.^[10]

In some cases, a person may have a weakened immune system due to illness or medication. For these individuals, a fifth vaccine dose may be recommended on day 28 to ensure adequate immune response.^[14] The rabies vaccine works by training the immune system to recognize and attack the rabies virus. It contains inactivated (dead) virus particles that cannot cause disease but are enough to stimulate antibody production. Over the course of the vaccine series, the body builds up a strong defense that will destroy any rabies virus present in the body.^[1]

Common side effects of the rabies vaccine include pain, redness, or swelling at the injection site. Some people experience headaches, muscle aches, nausea, or abdominal pain.^[13] These reactions are generally mild and resolve within a few days. Serious allergic reactions are rare but possible, which is why vaccine administration should always occur in a medical setting where emergency treatment is available if needed.

In some situations, PEP can be stopped if the animal that caused the exposure is captured and tested. If laboratory analysis confirms the animal was not infected with rabies, the remaining vaccine doses can be safely discontinued.^[13] This is why reporting animal bites to local health authorities is so important—they can coordinate the capture and testing of animals, potentially sparing people from unnecessary treatment.

For individuals at ongoing high risk of rabies exposure—such as veterinarians, animal control officers, laboratory workers handling rabies virus, and people who work with wildlife—pre-exposure prophylaxis is recommended. This involves receiving the rabies vaccine before any exposure occurs. The pre-exposure series typically consists of two doses given on days 0 and 7.^[12] Pre-exposure vaccination does not eliminate the need for treatment after a rabies exposure, but it simplifies the protocol significantly. People who have been pre-vaccinated do not need HRIG and require only two vaccine doses instead of four after exposure, making treatment faster, less expensive, and easier to access—especially important for travelers in remote areas where medical care may be limited.^[14]

Healthcare workers who handle rabies specimens or work in rabies diagnostic laboratories face particularly high exposure risk. For these individuals, regular blood tests to measure antibody levels are recommended every six months, with booster vaccine doses given if antibody levels fall below protective thresholds.^[14]

Treatment in Clinical Trials and Experimental Approaches

Once rabies symptoms appear, the disease is almost invariably fatal, and no standard medical treatment can reverse it. This grim reality has driven researchers to explore experimental therapies, though with limited success. Unlike many diseases where clinical trials test drugs to improve outcomes, rabies research focuses on finding any intervention that might save lives after symptoms begin—a goal that has proven extraordinarily difficult.

The most well-known experimental approach is the Milwaukee Protocol, also called therapeutic coma. This treatment strategy was first attempted in 2004 when a teenager in Wisconsin survived rabies after being placed in a medically induced coma and given a combination of antiviral drugs and other medications.^[16] The theory behind this approach is that inducing coma might protect the brain while antiviral medications and the patient’s own immune system fight the virus. The drugs used include ketamine (an anesthetic), midazolam (a sedative), ribavirin (an antiviral), and amantadine (which affects neurotransmitters and has some antiviral properties).

However, the Milwaukee Protocol remains highly controversial and is not considered a proven treatment. While a small number of patients treated with this approach have survived—perhaps 10 to 20 cases worldwide—the vast majority have not, and many survivors suffered severe neurological damage.^[16] The protocol has been modified and attempted multiple times in different countries, but results have been inconsistent. Many experts believe that the few survivors may have been infected with less virulent strains of the rabies virus or may have mounted unusually strong immune responses for reasons not yet understood. The Milwaukee Protocol is not FDA-approved and is generally considered experimental palliative care rather than a reliable cure.

Research into monoclonal antibodies represents another area of investigation. Unlike HRIG, which contains a mixture of different antibodies from many donors, monoclonal antibodies are laboratory-produced proteins designed to target specific parts of the rabies virus. These experimental antibodies could potentially replace HRIG in post-exposure prophylaxis, offering advantages such as more consistent potency, lower risk of transmitting blood-borne infections, and easier production in large quantities. Several monoclonal antibody candidates have undergone testing, but as of now, none have replaced HRIG in standard clinical practice in the United States, though some are used in other countries where HRIG is less available.^[14]

Scientists are also investigating improved rabies vaccines that might provide faster or stronger immune responses. Traditional rabies vaccines require multiple doses over two weeks, which can be logistically challenging and expensive. Researchers are exploring vaccines that could provide protection with fewer doses or work more quickly. Some experimental approaches involve combining vaccine with immune-stimulating compounds called adjuvants that might enhance the body’s immune response, potentially reducing the number of doses needed.

Gene therapy approaches, while still in very early research stages, offer theoretical possibilities. One concept involves using harmless viruses to deliver genetic instructions that would cause cells to produce rabies-fighting antibodies or interfere with the rabies virus’s ability to spread through nerve cells. However, these approaches remain years away from human testing and face significant scientific and safety hurdles.

Immunotherapy research has examined whether other immune-boosting treatments might help. Some studies have looked at interferons, proteins that cells naturally produce to fight viral infections, to see if giving them as medication might help combat rabies once infection is established. However, results have been disappointing, with interferons showing limited effectiveness against rabies in both laboratory and clinical settings.

Clinical trials for rabies treatments are extremely rare and face unique ethical and practical challenges. Because post-exposure prophylaxis is so effective at preventing rabies, it would be unethical to withhold it from exposed individuals to test experimental treatments. This means clinical trials can only include people who develop symptoms despite treatment or who did not receive timely PEP. These cases are fortunately rare, making it difficult to gather enough patients to conduct rigorous scientific studies.

Research into rabies also includes efforts to better understand how the virus attacks the nervous system at the molecular level. Scientists have identified specific proteins on the rabies virus surface that allow it to bind to nerve cells and inject its genetic material. Understanding these mechanisms might eventually lead to drugs that block the virus’s ability to infect cells or spread through the nervous system, though such treatments remain theoretical at this stage.

Most rabies research today focuses not on treating established disease but on improving prevention strategies. This includes developing better diagnostic tests that can detect rabies exposure earlier, creating more stable vaccines that don’t require refrigeration (important for use in remote areas), and finding ways to make HRIG more affordable and accessible in developing countries where dog rabies is common but medical resources are limited.^[2]

Most common treatment methods

• Post-Exposure Prophylaxis (PEP) for Previously Unvaccinated Individuals
  • Immediate thorough wound washing with soap and water for at least 15 minutes, followed by antiseptic application
  • Human rabies immune globulin (HRIG) injected into and around the wound site as soon as possible, with any remaining dose given intramuscularly
  • Four-dose rabies vaccine series administered intramuscularly on days 0, 3, 7, and 14
  • Fifth vaccine dose on day 28 for immunocompromised individuals
• Post-Exposure Prophylaxis for Previously Vaccinated Individuals
  • Thorough wound washing with soap and water
  • Two-dose rabies vaccine series on days 0 and 3 (no HRIG needed)
• Pre-Exposure Prophylaxis
  • Two-dose rabies vaccine series given on days 0 and 7 for individuals at high risk of exposure
  • Regular antibody titer monitoring every six months for high-risk laboratory workers and veterinarians
  • Booster doses when antibody levels fall below protective thresholds
• Experimental Treatment for Symptomatic Rabies
  • Milwaukee Protocol involving medically induced coma with ketamine and midazolam
  • Combination of antiviral medications including ribavirin and amantadine
  • Supportive intensive care with monitoring of brain function and vital signs
  • Note: This approach remains experimental with very low success rates and is not standard medical practice